PELLMOFY Trademark

Trademark Overview

On Tuesday, April 2, 2024, a trademark application was filed for PELLMOFY with the United States Patent and Trademark Office. The USPTO has given the PELLMOFY trademark a serial number of 98479643. The federal status of this trademark filing is NON-FINAL ACTION - MAILED as of Wednesday, October 16, 2024. This trademark is owned by Constellation Pharmaceuticals, Inc.. The PELLMOFY trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of blood diseases; pharmaceutical preparations for the treatment of diseases of the bone marrow; pharmaceutical preparations for the treatment of cancer, namely, BET protein inhibitors; pharmaceutical preparations for the treatment of myelofibrosis; pharmaceutical preparation for the treatment of myelodysplastic syndrome (MDS); pharmaceutical preparations for the treatment of myeloproliferative neoplasm; pharmaceutical preparations for suppressing tumors; pharmaceutical preparations for the treatment of thrombocythemia; pharmaceutical preparations for the treatment of diseases that involve dysregulation of epigenetic pathways; pharmaceutical preparations for epigenetic modulators as therapeutics; pharmaceuticals comprising small molecules; small molecule compounds for medical use and drug delivery; small molecule pharmaceuticals for the treatment of diseases and conditions; pharmaceut...
pellmofy

General Information

Serial Number98479643
Word MarkPELLMOFY
Filing DateTuesday, April 2, 2024
Status641 - NON-FINAL ACTION - MAILED
Status DateWednesday, October 16, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements

Goods and ServicesPharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of blood diseases; pharmaceutical preparations for the treatment of diseases of the bone marrow; pharmaceutical preparations for the treatment of cancer, namely, BET protein inhibitors; pharmaceutical preparations for the treatment of myelofibrosis; pharmaceutical preparation for the treatment of myelodysplastic syndrome (MDS); pharmaceutical preparations for the treatment of myeloproliferative neoplasm; pharmaceutical preparations for suppressing tumors; pharmaceutical preparations for the treatment of thrombocythemia; pharmaceutical preparations for the treatment of diseases that involve dysregulation of epigenetic pathways; pharmaceutical preparations for epigenetic modulators as therapeutics; pharmaceuticals comprising small molecules; small molecule compounds for medical use and drug delivery; small molecule pharmaceuticals for the treatment of diseases and conditions; pharmaceuticals and pharmaceutical preparations for human use for the treatment and prevention of diseases and disorders; antibodies sold as a component ingredient of pharmaceuticals; antibodies for use in the manufacture of active ingredients of pharmaceuticals and vaccines; diagnostic preparations for medical purposes; biological substances for human medical diagnostics and analysis; clinical medical reagents; biological preparations for medical purposes; pharmaceutical and veterinary preparations, agents and substances

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, April 2, 2024
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameConstellation Pharmaceuticals, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressBoston, MA 02210

Trademark Events

Event DateEvent Description
Tuesday, April 2, 2024NEW APPLICATION ENTERED
Tuesday, April 2, 2024NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, October 15, 2024ASSIGNED TO EXAMINER
Wednesday, October 16, 2024NON-FINAL ACTION WRITTEN
Wednesday, October 16, 2024NON-FINAL ACTION E-MAILED
Wednesday, October 16, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED

Related Keywords

pellmofy pharmaceutical treatment preparations diseases small molecule epigenetic pharmaceuticals cancer comprising